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doi:10.1016/j.ejvs.2010.04.013Abstract Objectives: To test the hypothesis that vein graft intimal hyperplasia can be signif-
icantly suppressed by a single intra-operative transfection of the graft with a decoy oligonucle-
otide (ODN) binding the transcription factor Egr-1.
Design: Experimental study.
Materials and methods: Jugular vein to carotid artery interposition grafts in rabbits were
treated with Egr-1 decoy, mutant decoy ODN, vehicle alone, using a non-distending pressure
of 300 mmHg for 20 min, or were left untreated. All animals were fed a 2% cholesterol diet.
The animals were sacrificed after 48 h, 6 weeks and 12 weeks. Paraffin-embedded vein
sections were subjected to angiometric analysis.
Results: Successful delivery of the ODN was confirmed by DAPI staining. Quantitative real-time
PCR revealed a 60% decrease of the Egr-1 gene expression in the animals in which the Egr-1
decoy ODN was delivered. Cellular proliferation was also significantly decreased as indicated
by the Ki-67 labelling index. An increase in intimal and medial thickness was found in all vein
grafts. However, intimal thickness was significantly reduced in the grafts treated with Egr-1
decoy ODN, whereas luminal area was significantly increased.
Conclusion: A single intra-operative pressure-mediated transfection of vein grafts with Egr-1
decoy ODN significantly suppresses intimal hyperplasia in a rabbit hypercholesterolaemic
model.
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Treatment of Intimal Hyperplasia by Egr-1 Decoy ODN 217More than a century after their initial description by Carrel
and Guthrie in 1906, vein grafts remain the best arterial
substitute for peripheral vascular reconstruction, despite
the significant progress in the technology of synthetic
bypass grafts.1,2 The main cause of failure of vein grafts is
the development of intimal hyperplasia.3,4 Although several
approaches, such as pharmacologic agents, external
sheaths and stents, external radiation, brachytherapy or
photodynamic therapy, have been tried for the prevention
of intimal hyperplasia, none of them has solved the prob-
lem.5e10 Recent advances in the understanding of the
intracellular molecular mechanisms mediating the devel-
opment of intimal hyperplasia have provided novel targets
for preventive and therapeutic interventions.11e13
Egr-1 (early growth response factor-1) is a zinc finger
transcription factor, first identified by Sukhatme and
colleagues in 1988.14 It is expressed in several cell types in
the vascular wall, including endothelial cells (ECs), vascular
smooth muscle cells (SMCs), monocytes and macrophages.
Egr-1 expression is induced by multiple stimuli associated
with the development of vascular diseases, such as shear
stress, mechanical stress, hypoxia, insulin and glucose,
angiotensin II and acute arterial injury.15e17 Once acti-
vated, Egr-1 induces the expression of multiple pro-
inflammatory genes involved in atherosclerosis, such as
monocyte chemotactic protein-1 (MCP-1), tumour necrosis
factor a (TNFa) and intercellular adhesion molecule-1
(ICAM-1), as well as the expression of genes, such as
fibroblast growth factor-2 (FGF-2), platelet-derived growth
factor (PDGF) and transforming growth factor-b (TGF-b),
implicated in the proliferative and chemotactic response to
injury leading to intimal hyperplasia and restenosis.15e17
The aim of our study was to test the hypothesis that
a single intra-operative pressure-mediated transfection of
jugular vein to carotid artery interposition grafts with Egr-1
decoy oligonucleotide (ODN) would significantly suppress




A double-stranded Egr-1 decoy phosphorothioate-stabilised
ODN, (Invitrogen Corporation, Carlsbad, CA, USA) which
contains two copies of 50-GCGGGGGCG-30 representing the
Egr-1 consensus binding sequences, was synthesised.18 The
mutant Egr-1 decoyODNused as a negative control contained
the following sequence: 50-GCTAGGGCG-30.18 TheODNswere
dissolved at a concentration of 40 mmol l1 in normal saline
solution. Fluorescein isothiocyanate-labelled Egr-1 decoy
ODN (FITC-ODN) was used for fluorescent microscopic eval-
uation of ODN distribution after transfection.
Experimental animal model and ex-vivo
transfection
Sixty-six male New Zealand white rabbits (Oryctolagus
cuniculus) 12e15 weeks old, weighing 3e3.5 kg were used
in this experiment. The experimental protocol was
approved by the ethics committee of the Foundation ofBiomedical Research. The animals were housed individually
and cared for in accordance with the guiding principles of
the American Physiological Society and the Greek Presi-
dential Decree 160/1991, issued after the European Union
Directive 609/1986.
All animals were fed a diet containing 2% cholesterol
starting 1 week before the operation until the time of vein
graft harvest. At operation, animalswere premedicatedwith
intramuscular administration of xylazine (2e5 mg kg1) and
ketamine (25e50 mg kg1) and were mechanically venti-
lated after tracheal intubation (VMS, MDS Matrix, USA).
Anaesthesia was maintained with the administration of iso-
flurane (2.05% Forenium, Abbott, Abbot Park, IL, USA). The
auricular vein was catheterised for fluid administration.
Heart rate, respiratory rate, SpO2, electrocardiograph
(ECG), rectal temperature, systolic, diastolic and mean
arterial pressure were continuously monitored (Passport 2,
Datascope, USA). A midline vertical neck incision was per-
formed and a 2.5-cm segment of the right external jugular
vein was harvested using a non-touch technique. The vein
graft was cannulated distally with a 22-G vein catheter and
secured with a 3/0 silk tie. The proximal end remained open
and the graft was flushed gently with normal saline solution.
The graft was surrounded by a plastic sheath, which was
mounted proximally on the vein catheter with a 2 silk suture.
The ODN solution (decoy, mutant decoy or fluorescent iso-
thyocyanate (FITC)) or vehicle alonewas infused through the
cannula so that both the lumen of the vein and the
surrounding space were bathed in the fluid. The plastic
sheath was clamped distally and the fluid was pressurised to
300 mmHg with the use of a balloon inflation device (Styker
Diskmonitor).
Heparin (200 U kg1) was administered intravenously and
the ipsilateral common carotid artery was clamped proxi-
mally and distally and divided. The vein graft was anasto-
mosed to the divided artery in a reversed end-to-end
fashion with interrupted 7/0 polypropylene sutures. After
removal of the arterial clamps, the proximal and distal ends
of the common carotid artery were treated with lidocaine
2% and the wound was closed. All animals recovered in the
Intensive Care Unit under continuous monitoring.
Animals were divided in five groups. Vein grafts in group
A (12 animals) received treatment with Egr-1 decoy solution
(40 mmol l1); in group B (18 animals) they were treated
with mutant decoy ODN (40 mmol l1); while in group C (12
animals), vein grafts were treated with vehicle alone. Vein
grafts in group D (18 animals) received no treatment, while
grafts in group E (six animals) were treated with FITC-
labelled decoy (FITC-ODN). Half of the animals in groups
A and C were sacrificed after 6 weeks and the other half
after 12 weeks. One-third of the animals in groups B and D
were sacrificed after 48 h, one-third after 6 weeks and the
other third after 12 weeks. Grafts excised after 6 and 12
weeks were carefully dissected to remove adherent tissue,
perfusion fixed in situ at 80 mmHg, and harvested and
processed for routine paraffin embedding. Grafts excised
after 48 h were homogenised and subjected to quantitative
real-time reverse transcription polymerase chain reaction
(RT-PCR) to evaluate Egr-1 expression.
Animals in group E were sacrificed after 48 h, following
verification of their patency by colour Duplex scan. The
vein grafts were removed and divided in two segments. One
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staining with 40,6-diamidino-2-phenylindole (DAPI) (Roche
Molecular Biochemicals, Indianapolis, IN, USA) to measure
transfection efficiency, whereas the other half was homo-
genised and analysed with the use of RT-PCR to evaluate
Egr-1 expression.
Vessel morphometry
Extents of 5-mm cross sections from the middle of the vein
grafts as well as from the contralateral external jugular
vein were treated with haematoxylineeosin and sirius red
for collagen staining and with Orcein for elastin staining. All
measurements were conducted using image-processing
software (Image-Pro Plus v4.5; Media Cybernetics Inc, Silver
Spring, MD, USA) on polychromatic images taken by a digital
camera (Altra20; Soft Imaging System, Munster, Germany)
coupled to light microscopy (Olympus CX31; Olympus,
Tokyo, Japan). Thickness and area were determined under
suitable magnification from haematoxylin and eosin-stained
sections. Measurements of wall thickness and of intimal and
medial thickness were performed in 20 representative
optical fields every 18 around the vessel circumference in
appropriately stained sections. For each animal, three cross
sections were measured for calculating mean values. Neo-
intima was distinguished by its position relative to the
internal elastic lamina and by its chaotic organisation of
cells compared with the circumferential arrangement of
medial SMCs. All measurements in each sample were made
by two independent observers blinded to treatment
allocation.
Reverse transcription quantitative real time PCR
Real-time RT-PCR was performed to confirm Egr-1 mRNA
expression in vein grafts from O. cuniculus. Total RNA was
isolated using TriReagent (Sigma) with DNase treatment
(RNase-Free DNase Kit, Qiagen). Reverse transcription was
performed using MMLuV RT (Promega) and random primers.
PCR primers were designed using Beacon Designer 7.0 soft-
ware (Premier Biosoft, Palo Alto, CA, USA). The primers for
O. cuniculus Egr-1 were as follows: forward: 50-CCCGAC-
TACCTGTTTCCG-30; reverse: 50-GTGGAGAGTGGAGTGAGG-30.
The primers for b-actin were as follows: forward:
50-TGTCCCTGTACGCCTCTG-30, reverse: 50-CGTAGCCCTCG-
TAGATGG-30. The primers were tested for specificity by
conventional PCR. Reaction conditions were optimised, and
cDNA samples were subjected to PCR amplification using
SybrGreenERPCRSuperMix (InvitrogenCorporation,Carlsbad,
CA, USA) using the Chromo4 Real-Time PCR Detection System
(Bio-Rad, Hercules, CA, USA). Values were determined using
Opticon Monitor 3 software (Bio-Rad) and normalised to
b-actin. The 2DDCt methodwas used for quantification of the
target gene.19
Immunohistochemical staining technique for Ki-67
Serial embedded paraffin sections of vein grafts were
incubated with an anti-mouse Ki-67 monoclonal antibody
(DAKO, Glostrup, Denmark) at a dilution of 1:80 for 90 min
at 37 C to identify cell proliferation. Antibody binding wasvisualised using the labelled streptavidinebiotin (LSAB)
method (DAKO LSAB Kit), and 3,3-diaminobenzidine. Then,
cell nuclei were counterstained with haematoxylin and
mounted with DPX. The percentage of Ki-67 positive cells
among the total number of cells (Ki-67 labelling index) was
measured on three cross-sections and mean values were
calculated for each group.
Statistical analysis
All values are expressed as mean SE. Statistical analysis
was performed using Student’s t-test and one-way analysis
of variance (ANOVA) followed by the Bonferroni multiple
comparison test. Analyses were conducted using SPSS 16.0
for Windows (SPSS Inc, Chicago, IL, USA).
Results
No morbidity or mortality was observed in any of the
groups. Serum total cholesterol levels ranged between 35
and 70 mg dl1 before the initiation of the 2% cholesterol
diet and increased to 1000e2100 mg dl1 after 1 week
(P< 0.01). These high cholesterol levels were sustained
throughout the experiment.
Transfection efficiency
Successful transfection of ECs and SMCs was demonstrated
by DAPI staining of vein grafts in group E, showing that the
nuclear FITC signal was clearly stronger than that of the
cell cytoplasm, thereby documenting nuclear localisation
of ODN (Fig. 1).
Functional gene blockade
Quantitative real-time PCR of vein segments in groups B, D
and E revealed that Egr-1 decoy ODN transfection achieved
a 57% and 60% inhibition of Egr-1 mRNA concentration
compared with vein grafts transfected with mutant decoy
ODN or vein grafts that were not treated, respectively
(Fig. 2).
Inhibition of proliferation
At 6 weeks, the Ki-67 labelling index in vein grafts treated
with Egr-1 decoy ODN was 44% lower compared with vein
grafts treated with mutant decoy ODN, 34% lower compared
with grafts treated with vehicle alone and 41% lower
compared with vein grafts without any treatment (Fig. 3).
The statistically significant difference was sustained at 12
weeks, with the Ki-67 labelling index in group A being 40%
lower than in group B, 35% lower than in group C and 39%
lower than in group D.
Inhibition of intimal hyperplasia
Development of eccentric atherosclerotic plaques, intimal
and medial hyperplasia as well as an increase in collagen
density was found in all vein grafts (Fig. 4). However, intimal
thickness in the grafts treated with Egr-1 decoy ODN
Figure 1 Nuclear localization of FITCeODN in jugular vein graft of rabbit model. Fluorescent photomicrographs indicate
concentrated green FITCeODN signals (A), that correspond to nuclei labeled with the DAPI coloration (B), as seen in detail in the
merged image (C). (Original magnification 20, scale bar: 200 mm).
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weeks compared with the grafts that were treated with
mutant decoy ODN (167.2 17.3 mm, range 96.0e204.1 mm),
42% lower compared with the grafts that were treated with
vehicle alone (145.0 20.1 mm, range 97.0e210.0 mm) and
41% lower compared with the grafts that were untreated
(144.5 18.2 mm,range95.3e188.1 mm)(Fig. 5).At12weeks,
intimal thickness in the grafts treated with Egr-1 decoy ODN
(95.8 1.7 mm, range 92.6e97.3 mm) was 32%
(145.9 11.1 mm, range 106.8e188.0 mm), 30% (142.7
21.6 mm, range 92.6e210.4 mm) and 36% (153.2 15.8 mm,
range 102.5e199.5 mm) lower, respectively (Fig. 5). No
significant difference in intimal thickness was found between
vein grafts treated with mutant decoy ODN, vehicle alone or
vein grafts that were untreated. No statistically significant
difference was also found in overall or medial thickness
between the various groups (Fig. 5).
The intimal cross-sectional area in the Egr1 decoy ODN
group was 54%, 45% and 41% lower compared with the
mutant ODN, vehicle alone and the untreated vein grafts
respectively at 1.5 months and 39%, 35% and 40% lower,
respectively, at 3 months (Fig. 6). No significant difference
was found in medial thickness between the various groups.
On the contrary, lumenal area was significantly increased in
the Egr-1 decoy ODN group, being 28%, 32% and 35% larger
compared with the mutant ODN, vehicle alone and the
untreated vein grafts, respectively, at 1.5 months and 39%,
29% and 44% larger, respectively, at 3 months (Fig. 7).Figure 2 Egr-1 mRNA expression in qRTePCR. Egr-1 expres-
sion was 60% and 57% lower in the decoy treated grafts
compared to the untreated and mutant ODN treated grafts,
respectively (nZ 6 for each group, ** P< 0.001).Discussion
Intimal hyperplasia of vein grafts is a multifactorial
process, triggered by vascular injury, altered haemody-
namic stresses, vasospasm, inflammation and ischaemia.
Even more complex are the intracellular pathways medi-
ating the response of the vascular wall to these stimuli. The
signalling pathways involve inhibitory proteins, such as the
retinoblastoma protein, p21, p27 and p53, as well as pro-
proliferative proteins, such as cyclin-dependent kinases
(cdks) and PCNA.20 It is therefore clear that inhibition or
promotion of a single pathway will have limited success in
preventing intimal hyperplasia. In this context, transcrip-
tion factors are of particular importance since they are
a point of integration of multiple signalling pathways that
regulate a coordinated cellular response.
Transcription factors that have been used as targets for
decoy ODNs include E2F, nuclear factor-kappa B (NFkB),
activator protein-1 (AP-1) and the CCAAT/enhancer binding
protein (C/EBP). Intra-operative transfection of jugular
vein to carotid artery interposition grafts with E2F decoy
ODN yielded an inhibition to neointimal hyperplasia and
atherosclerotic plaque formation over 6 months in hyper-
cholesterolaemic rabbits.21 In humans, E2F-decoy-treated
infrainguinal vein grafts had fewer occlusions, revisions or
arterial stenoses at 12 months.22 On the contrary, E2F
decoy proved to be no more effective than placebo in
preventing angiographic graft failure, acute adverse
effects, or major adverse cardiac events 12e18 months
after coronary artery bypass graft (CABG).23
In a similar animal model, intra-operative treatment of
jugular vein grafts with NFkB decoy ODN significantly sup-
pressed intimal hyperplasia (by about 50%) 4 weeks after
implantation, increased medial thickening and suppressed
inflammatory changes and accumulation of vascular SMCs in
the neointima of rabbit vein grafts.24 The usefulness and
safety of the NFkB decoy ODN transfer has also been tested
in clinical practice, in 17 patients submitted to percuta-
neous coronary interventions (PCIs).25 Six months after the
PCI and decoy ODN transfection, significant restenosis was
found in only one of the 17 patients. No in-stent thrombosis
was found and no significant systemic adverse effect
occurred in any of the patients during this observation
period.
In a rabbit model of restenosis that combines balloon
injury of the carotid artery with cholesterol-mediated
Figure 3 a. Photomicrographs showing representative cross sections of vein grafts treated with Egr-1 decoy ODN (A), mutant ODN
(B), vehicle alone (C) and vein grafts without any treatment (D) 1.5 month after placement in ipsilateral carotid artery (immu-
nohistochemical staining for Ki-67, original magnification 20, scale bar: 200 mm). b. Inhibitory effect of Egr-1 decoy transfection
on proliferation (Ki-67 positive cells) at 1.5 and 3 months after placement of vein grafts treated with Egr-1 decoy ODN (A), mutant
ODN (B), vehicle alone (C) and vein grafts without any treatment (D) (nZ 6 for each group, * P< 0.05).
Figure 4 Light micrographs of normal vein (a), Egr-1 decoy ODN-treated vein grafts (b) and mutant decoy ODN-treated vein grafts
(c) in hypercholesterolemic rabbits 3 months after grafting. An intimal and medial hyperplasia is seen in the vein grafts compared
to the normal vein (hematoxylin-eosin stain: original magnification 5. scale bar: 500 mm).
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C/EBP achieved a significant reduction (up to 50%) of neo-
intimal formation and intravascular inflammation.26 Other
authors have used the haemagglutinating virus of Japan
(HVJ)-liposome technique to transfect AP-1 decoy ODN into
rat carotid arteries.27,28 The AP-1 decoy ODN, introduced in
this way, significantly reduced neointimal formation after
balloon injury to the rat carotid artery.
The quest of the ideal target to treat bypass failure is
stronger than ever, though one might argue that the ideal
target exists. The dream of the discovery of a single tran-
scription factor, the binding of which would be enough by
itself to prevent intimal hyperplasia might prove elusive.
Our study adds another transcription factor, Egr-1, the
binding of which with an ODN achieved a smaller but still
statistically significant suppression of intimal hyperplasia
by about 40% at 6 weeks and 30% at 3 months.
Prompted by the finding that multiple processes partici-
pate in the formation of neointimal hyperplasia, Miyake et al.
developed a chimeric decoy ODN approach, assessing the
effect of simultaneous inhibition of NFkB and E2F on the
formation of neointimal hyperplasia.29 A 2-cm diameter pol-
ytetrafluoroethylene (PTFE) graft was placed in the carotid
artery in an end-to-end fashion in hypercholesterolaemic
rabbits andchimericdecoyODNswere introduced inbothends
of the carotid artery using pressure-mediated transfection.
Treatment with chimeric decoy ODN significantly inhibitedFigure 5 Intimal and medial wall thickness at 1.5 and 3 months a
mutant ODN (B), vehicle alone (C) and vein grafts without any treat
decoy ODN versus mutant ODN, vehicle alone and the untreated
months and 32%, 30% and 36% reduced respectively at 3 months (
(mm), black bars: medial thickness (mm).proximal and distal anastomotic intimal hyperplasia, SMC
proliferation and macrophage accumulation, whereas it
accelerated re-endothelialisation.
The reason why most relevant studies, including ours,
have used a hypercholesterolaemic diet,18,21,24,29 is that
the rabbit hypercholesterolaemic model is considered as
the most relevant and appropriate for studying novel
approaches against human restenosis.18 That is because
hypercholesterolaemia has been shown to induce acceler-
ated development of intimal hyperplasia in experimental
vein grafts.30
A critical point in all transfection studies is the effi-
ciency of the transfection. Gene transfer methods can be
roughly divided into two major categories, viral and non-
viral. The most commonly used non-viral approaches are
direct incubation with naked DNA and coupling of DNA with
lipophylic/hydrophobic agents.
The use of naked DNA is simple and safe but carries the
risk of extracellular nuclease degradation. Coupling the
DNA with cationic phospholipids improves transfection
efficiency but may induce inflammation.31 Viral vectors, on
the other hand, produce a higher efficiency of gene transfer
but pose potential hazards of triggering an immune
response to the viral proteins. In our study, successful
delivery of the ODN into the nuclei of the target cells was
verified by DAPI staining, while inhibition of target gene
expression was confirmed by RT-PCR. The resulting 60%fter placement of vein grafts treated with Egr-1 decoy ODN (A),
ment (D) in cholesterol-fed rabbits. Intimal hyperplasia of Egr1
vein grafts was 50%, 42% and 41% reduced respectively at 1.5
nZ 6 for each group, * P< 0.05). Gray bars: intimal thickness
Figure 6 Intimal and medial cross-sectional wall area at 1.5 and 3 months after placement of vein grafts treated with Egr-1 decoy
ODN (A), mutant ODN (B), vehicle alone (C) and vein grafts without any treatment (D) in cholesterol-fed rabbits. The intimal area of
Egr1 decoy ODN versus mutant ODN, vehicle alone and the untreated vein grafts was 54%, 45% and 41% reduced respectively at 1.5
months and 39%, 35% and 40% reduced respectively at 3 months (nZ 6 for each group,** P< 0.001,*** P< 0.0001). Gray bars:
intimal area (mm2), black bars: medial area (mm2).
222 M. Peroulis et al.decrease in Egr-1 mRNA concentration is quite satisfactory
and proved to be enough to achieve a therapeutic effect.
The major drawback of antisense ODNs is their relatively
fast nucleolytic degradation. The superior stability of short
interfering RNA (siRNA) makes it a promising strategy of
gene inhibition and is currently studied in different disease
models. In a recently published study, local lentiviral short
hairpin RNA silencing of CCR2 reduced vein graft thickening
in hypercholesterolaemic apolipoprotein E3-Leiden mice by
38%, 4 weeks after surgery.32
A theoretical question that might be raised is how an
intra-operative vein graft transfection could have a pro-
longed or, ideally, permanent beneficial effect on the vein
wall. The answer is that target gene inhibition does not
necessarily need to be permanent. During the first few
weeks after implantation, the vein graft recovers from the
acute traumatic, ischaemic and inflammatory injuries
associated with grafting and becomes less susceptible toFigure 7 Effect of Egr-1 decoy transfection in lumenal area
1.5 and 3 months after placement of vein grafts treated with
Egr-1 decoy ODN (A), mutant ODN (B), vehicle alone (C) and
vein grafts without any treatment (D) in cholesterol-fed
rabbits. The lumen area of Egr-1 decoy ODN versus scrambled
ODN, vehicle alone and the untreated vein grafts was 28%, 32%
and 35% increased respectively at 1.5 months and 39%, 29% and
44% increased respectively at 3 months (nZ 6 for each group, *
P< 0.05, ** P< 0.001).neointimal hyperplasia and accelerated atherosclerosis. In
any case, of course, the strategy with the more permanent
effect would probably be more beneficial, combating not
only the acute response to the new haemodynamic envi-
ronment but also the effect of other patient-related risk
factors, such as smoking or hypercholesterolaemia. The use
of techniques with a more permanent effect (such as
siRNA), chimeric decoy ODNs (targeting more than one
transcription factors) and optimised introduction methods
may revive the interest in decoy ODN clinical research
which was diminished after the failure of E2F decoy to
inhibit restenosis in coronary artery bypass grafts.
In conclusion, ODN delivery in vein grafts interimposed
in the carotid arteries was achieved by only increasing the
hydrostatic pressure and without using a specific vehicle.
Inhibition of Egr-1 expression seems to contribute in the
significant reduction in the development of neointimal
hyperplasia. These results are encouraging in the context of
decelerating neointimal hyperplasia progression, while the
proposed method is technically simple and efficient, low
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